
Type 2 cytokine Fc-IL-4 can directly act on CD8+ T cells to enrich and reinvigorate terminally exhausted CD8+ T cells, thereby enhancing the efficacy of type 1 immunity-based cancer immunotherapies.


coremsg

Fc–IL-4, a typical type 2 cytokine, reinvigorates exhausted CD8+ T cells in tumours, underscoring this fusion protein as a potent immunotherapy that synergizes effectively with type 1 immunity against cancer.

The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer - Nature

harnessing-type-2-immunity-to-revitalize-exhausted-cd8-t-cells-and-enhance-cancer-immunotherapy


Harnessing Type 2 Immunity to Revitalize Exhausted CD8+ T Cells and Enhance Cancer Immunotherapy
